Therapeutic workshops

Our workshops can be delivered in person or virtually to medicines optimisation team members and / or practice-based pharmacists and technicians, GPs and nurse prescribers and provide an opportunity to:

  • update clinical knowledge
  • be aware of the latest national guidance
  • network with colleagues
  • consider local implementation to support best practice and patient care

The format is a mix of lecture-style presentations and case studies plus plenty of opportunities for interaction. They also support professional revalidation.

See the sliders below for more detail on the content for each workshop and to download the flyer.

The workshops cost £1,250 + VAT for one or £3,375 for three workshops if booked together (a saving of £375).

For a face to face workshop, the hosting organisation will need to provide the venue, plus any refreshments. We suggest a maximum of approximately 40 attendees.

Virtual workshops are held on Microsoft Teams.

If you are interested in commissioning a workshop or would like further information please contact us elearning@prescqipp.info

  • NICE guideline 196; assessing stroke and bleeding risk
  • Anticoagulant treatment options
  • Choice of anticoagulant
  • Safe prescribing of DOACs in people with renal impairment
  • Co-prescribing of anticoagulants and antiplatelets
  • Patient information for people taking anticoagulants

PLEASE NOTE: Our Asthma therapeutic workshop is currently unavailable as we are updating it in line with the new NICE guideline, published on 27th November 2024.

  • Diagnosis (brief overview)
  • Triggers and co-morbidities
  • Differences between asthma and COPD
  • Asthma guidelines
  • Steroid cards
  • NRAD report
  • Asthma review
  • How inhalers impact the environment and contribute to climate change
  • National guidance, NHS targets and activities supporting a reduction in inhaler carbon emissions
  • Inhaler carbon emission data and how to use it
  • Inhaler switch strategies
  • Strategies to support reductions in inhaler carbon emissions which aim to also improve patient outcomes
  • Environmentally safe disposal or recycling of inhaler

  • Background to chronic heart failure
  • Classification of chronic heart failure
  • The heart failure clinical team
  • Diagnosis
  • First-line treatments
  • Specialist treatments
  • Treatment pathways
  • Lifestyle

  • World Health Organisation Medication Without Harm Challenge
  • Public Health England Prescribed Medicines Review
  • Implementation resources
  • Review and management of Dependence Forming Medicines including:
    • opioids for chronic, non-cancer pain
    • Benzodiazepines
    • Z drugs
    • Gabapentin
    • Pregabalin

  • Background to Evidence Informed Decision Making
  • Finding evidence; checking validity and relevance
  • Types of evidence including:
    • case control studies
    • cohort studies
    • Randomised Controlled Trials
    • systematic reviews
    • meta analyses
  • Making sense of the numbers including:
    • absolute risk
    • relative risk
    • numbers needed to treat/harm
    • p values
    • confidence intervals
  • How clinicians make decisions
  • Shared decision making

  • Cardiovascular statistics and risk factors
  • Cholesterol and hypercholesterolaemia
  • NICE Guideline 238
  • Statins
  • Ezetimibe
  • PCSK9 inhibitors
  • Bempedoic acid
  • Inclisiran
  • National guidance for lipid management

  • Polypharmacy and deprescribing – the theory
    • Definitions and evidence base
    • International and national resources
    • Frailty, multimorbidity and end of life
  • Polypharmacy and deprescribing – practical issues
    • Agreeing treatment goals
    • Shared decision making and patient decision aids
    • Medication review and tools to help
  • Anticholinergic burden
    • Evidence base for cognitive impairment
    • ACB scales
    • NICE guideline 67 – use of anticholinergics in people with dementia
  • Medicines Optimisation Polypharmacy Prescribing Comparators

  • Chronic pain management focusing on NICE guideline 196
  • NICE guideline 215 on Medicines associated with dependence or withdrawal symptoms
  • The evidence for opioids in chronic pain
  • Adverse effects of opioids
  • Review and safe withdrawal of opioids
  • Patient and clinician resources to support implementation